Mira Pharmaceuticals (MIRA) Net Cash Flow (2022 - 2025)

Mira Pharmaceuticals has reported Net Cash Flow for 4 years, with the latest figure at $3.6 million in Q4 2025.

• Quarterly Net Cash Flow rose 377.55% year-over-year to $3.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.5 million (up 296.41% YoY) and the FY2025 annual result came in at $3.5 million, up 296.41% from the prior year.
• Net Cash Flow improved to $3.6 million in Q4 2025 per MIRA's latest filing, from $1.9 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $5.8 million in Q3 2023 and troughed at -$1.6 million in Q1 2025.
• A 4-year average of $391614.8 and a median of -$397880.5 in 2023 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2023 and 2024: Net Cash Flow soared 1015.1% in 2023, then sank 3102.96% in 2024.
• Over 4 years, Net Cash Flow stood at $163563.0 in 2022, then plunged by 873.87% to -$1.3 million in 2023, then fell by 3.62% to -$1.3 million in 2024, then soared by 377.55% to $3.6 million in 2025.
• According to Business Quant data, Net Cash Flow over the past three periods registered $3.6 million, $1.9 million, and -$446132.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.